BD1.AU · BARD1 Life Sciences Limited

-

Please sign in to comment on BD1.AU

1 Comment

Admin

4 years, 1 month ago

BARD1 Life Sciences Limited is currently in a long term uptrend where the price is trading 6.6% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

BARD1 Life Sciences Limited's total revenue rose by 298.0% to $182K since the same quarter in the previous year.

Its net income has dropped by 108.7% to $-3M since the same quarter in the previous year.

Finally, its free cash flow fell by 220.4% to $-2M since the same quarter in the previous year.

Based on the above factors, BARD1 Life Sciences Limited gets an overall score of 3/5.

Industry	Healthcare
Exchange	AU
CurrencyCode	AUD
Sector	Health Care Providers & Services
ISIN	AU000000BD12

Target Price	None
Beta	-0.64
Market Cap	95M
PE Ratio	None
Dividend Yield	0.0%

ABOUT

BARD1 Life Sciences Limited

BARD1 Life Sciences Limited engages in the research, development, and commercialization of diagnostic products for the early detection of cancer to enhance patient outcomes in Australia. The company offers hTERT test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for ovarian and breast cancers, and research-stage projects for prostate and other cancers. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in Notting Hill, Australia.

BD1.AU · BARD1 Life Sciences Limited

-

BARD1 Life Sciences Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest BARD1 Life Sciences Limited using a moving average strategy